---
figid: PMC9707496__fonc-12-988138-g001
pmcid: PMC9707496
image_filename: fonc-12-988138-g001.jpg
figure_link: /pmc/articles/PMC9707496/figure/f1/
number: Figure 1
figure_title: ''
caption: Schematic diagram of FBW7-mediated oncogene and signaling pathway in T lymphoproliferative
  malignancies. 1) Dysregulation of FBW7 can reduce cellular levels of Notch intracellular
  Domain (NICD) degradation, which leads to abnormal activation of Notch pathway,
  NF-κB pathway, and affect the expression of its downstream substrates c-Myc, cyclin
  E. 2) T-cell acute lymphocytic leukemia 1 (TAL1) can upregulate miR-223 expression,
  thus reducing the expression of FBW7 and increasing the expression of downstream
  substrates c-Myc, Notch1, cyclin E, and Mcl-1 to induce cell proliferation. 3) FBW7
  mutations activate the RAF-MEK-ERK pathway, inhibiting BRAF degradation and providing
  resistance to BET inhibitors.
article_title: Dysregulation of FBW7 in malignant lymphoproliferative disorders.
citation: Xin Wan, et al. Front Oncol. 2022;12:988138.
year: '2022'

doi: 10.3389/fonc.2022.988138
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.

keywords:
- FBW7
- lymphoproliferative disorders
- ubiquitin
- Notch
- c-Myc

---
